Start of phase I of IL-2muFc Fusion protein (ALM223) in December. Phase I study of anti-IL-1RAP (ALM27134) with Ichnos Sciences. Partnerships with Academia Collaboration with CRG (Center for Genomic Regulation) to develop and characterize novel preclinical models for non-melanoma skin cancer in June. Collaboration with Barcelona Supercomputing Centre and Nostrum Biodiscovery project to seek new therapies through AI within the ARTIBAND project in December. Access to cutting-edge technology Partnership with Absci to develop novel treatments for dermatological diseases using AI-enabled antibody discovery technology in November. Multitarget alliance with etherna to develop mRNA-based therapies in medical dermatology in December. Advancing the impact of lebrikizumab The European Commission (EC) approved EBGLYSS® (lebrikizumab) in November for the treatment of adult and adolescent patients (aged 12 years and older, with a body weight of at least 40 kg) with moderate-to-severe atopic dermatitis (AD). Positive results from the ADvantage Phase IIIb study at 16 weeks were presented at the EADV Congress. Data from the long-term extension study, ADjoin, covering up to two years, were presented in Autumn 2023 at the Fall Clinical Congress. Initiation of additional studies: ADlong, ADvantage Germany extension, ADapt, ADmirable, ADorable1&2, and ADhope. Progressing our late-stage pipeline Tirbanibulin (actinic keratosis): Phase III clinical study for large field extension US completed. Supplementary NDA submitted to FDA in August. Launch expected in H2 2024 in the US. Sarecycline (acne): Phase III study for China met primary and secondary endpoints. NDA submission to Chinese Health Authorities in September. Efinaconazole (onychomycosis): Regulatory review on-going, and expected approval in H2 2024. Building our early-stage pipeline Licensing agreement with EpimAb Biotherapeutics to develop and commercialize bispecific antibodies using EpimAb’s proprietary FIT-Ig® platform in October. Milestones in 2023